Strategic partnerships Envision serves over 200 pharma and biotech clients including all top 20 firms, indicating a strong potential for expanding enterprise-level medical affairs, HEOR, and value evidence services within large, existing accounts.

Integrated tech edge With technology offerings such as Two Labs, Envision AI Labs, Riparian, and iEnvision alongside a modern tech stack (OpenAI, Google Cloud, Azure), there is a clear opportunity to cross-sell advanced AI driven medical communications, publication planning and market access analytics to deepen client impact.

Growth leadership Recent leadership expansions in commercial growth and talent acquisition signal a push to scale client acquisition and global headcount, presenting openings for you to target growth-stage programs and newly pursued market access initiatives.

Market access focus Riparian and market access leadership under new president suggests strong demand for pricing, value optimization, evidence generation, and payer strategies—ideal for offering expanded HEOR, pricing analytics, and real-world evidence services.

Expansion opportunities Upcoming iEnvision offerings and second-half 2026 portfolio launches create opportunities to pitch bundled solutions, onboarding programs, and managed services that integrate medical affairs, commercialization, and digital solutions across client portfolios.